The tweet was deleted by the author.
But we saved everything 🙂.
Rigel Pharmaceuticals today announced it has entered into an exclusive, global license agreement to develop, manufacture and commercialize VEPPANU, also known as vepdegestrant.
The company plans to advance the development of VEPPANU through this agreement and pursue worldwide commercialization opportunities. Investors and stakeholders can review further details in the official press release and listen to a webcast scheduled for today at 5:00 am ET.
Rigel Pharmaceuticals recently confirmed it will release Q1 2026 financial results and a business update on May 5. The scheduled update follows the company’s ongoing development and licensing activities. Financial performance and pipeline progress will be covered during that announcement.